Combining anticancer agents photodynamic therapy and LCL85 leads to distinct changes in the sphingolipid profile, autophagy, caspase-3 activation in the absence of cell death, and long-term sensitization

Documenti analoghi

• CATIONIC CERAMIDES AND ANALOGUES, LCL30 AND LCL85, AS ADJUVANTS TO PHOTODYNAMIC THERAPY OF TUMORS
  di: Korbelik, Mladen, et al.
  Pubblicazione: (2013)
• Enhanced Apoptotic Cancer Cell Killing after Foscan Photodynamic Therapy Combined with Fenretinide via De Novo Sphingolipid Biosynthesis Pathway
  di: Boppana, Nithin B., et al.
  Pubblicazione: (2016)
• Dose Dependent Actions of LCL521 on Acid Ceramidase and Key Sphingolipid Metabolites.
  di: Bai, Aiping, et al.
  Pubblicazione: (2018)
• C16-Ceramide Analog Combined with Pc 4 Photodynamic Therapy Evokes Enhanced Total Ceramide Accumulation, Promotion of DEVDase Activation in the Absence of Apoptosis, and Augmented Overall Cell Killing
  di: Duska Separovic, et al.
  Pubblicazione: (2011-01-01)
• C16-Ceramide Analog Combined with Pc 4 Photodynamic Therapy Evokes Enhanced Total Ceramide Accumulation, Promotion of DEVDase Activation in the Absence of Apoptosis, and Augmented Overall Cell Killing
  di: Separovic, Duska, et al.
  Pubblicazione: (2011)